Firma de capital de riesgo Foresite Capital revela la innovación biotecnológica en China, oportunidades en inmunología.
Recent big pharma asset acquisitions and new biotech company launches are showcasing a common theme: the drugs involved were originally developed in China. Foresite Capital, a venture capital firm, has obtained several of these drugs through regular trips to China since 2019. The competition for these assets has significantly increased, with big pharma now joining … Leer más